Erratum: Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing (Clinical Pharmacology and Therapeutics (2011) 89 (387-391) DOI: 10.1038/clpt.2010.320);Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 3, 2011, Pages 387-391

  Relling, M V ^a   Gardner, E E ^a   Sandborn, W J ^b   Schmiegelow, K ^c,d   Pui, C H ^a   Yee, S W ^e   Stein, C M ^f   Carrillo, M ^g   Evans, W E ^a   Klein, T E ^g  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Rigshospitalet   (Denmark)

^e San Francisco   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE TOXICITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER THERAPY; CLINICAL ASSESSMENT; DISEASE CONTROL; DNA SEQUENCE; DOMINANT INHERITANCE; DRUG ACTIVITY; DRUG INACTIVATION; DRUG PROTEIN BINDING; ENTERITIS; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; IMMUNE DEFICIENCY; LIVER TOXICITY; LYMPHOMA; MONOGENIC DISORDER; MYELOID LEUKEMIA; PANCREATITIS; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY; TREATMENT DURATION;

EID: 79951809968     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.152     Document Type: Erratum

References (33)

1. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 474-477.
2. Sandborn, W.J. Pharmacogenomics and IBD: TPMT and thiopurines. Inflamm. Bowel Dis. 10(suppl. 1), S35-S37 (2004).
3. Evans, W.E. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug Monit. 26, 186-191 (2004).
4. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
5. Ford, L.T. & Berg, J.D. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J. Clin. Pathol. 63, 288-295 (2010).
6. Black, A.J. et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716-718 (1998).
7. Relling, M.V. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 91, 2001-2008 (1999).
8. Lennard, L., Van Loon, J.A. & Weinshilboum, R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46, 149-154 (1989).
9. Lennard, L., Lilleyman, J.S., Van Loon, J. & Weinshilboum, R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336, 225-229 (1990).
10. Schaeffeler, E. et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14, 407-417 (2004).
11. Yates, C.R. et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126, 608-614 (1997).
12. Nygaard, U., Toft, N. & Schmiegelow, K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin. Pharmacol. Ther. 75, 274-281 (2004).
13. Evans, W.E. et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 19, 2293-2301 (2001).
14. Stocco, G. et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85, 164-172 (2009).
15. Higgs, J.E., Payne, K., Roberts, C. & Newman, W.G. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11, 177-188 (2010).
16. Lennard, L. & Lilleyman, J.S. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther. Drug Monit. 18, 328-334 (1996).
17. McBride, K.L., Gilchrist, G.S., Smithson, W.A., Weinshilboum, R.M. & Szumlanski, C .L. Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inhibited thiopurine methyltransferase deficiency. J. Pediatr. Hematol. Oncol. 22, 441-445 (2000).
18. Schwab, M. et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12, 429-436 (2002).
19. Gurwitz, D. et al. Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur. J. Hum. Genet. 17, 991-998 (2009).
20. Fargher, E.A. et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J. Clin. Pharm. Ther. 32, 187-195 (2007).
21. A ricó, M. et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29-30, 2005. Leukemia 19, 1145-1152 (2005).
22. Schmiegelow, K. et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 23, 557-564 (2009).
23. Relling, M.V., Altman, R.B., Goetz, M.P. & Evans, W.E. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11, 507-509 (2010).
24. A nstey, A.V., Wakelin, S. & Reynolds, N.J.; British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br. J. Dermatol. 151, 1123-1132 (2004).
25. C olletti, R.B. et al. Variation in care in pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 49, 297-303 (2009).
26. Sandborn, W.J. Rational dosing of azathioprine and 6-mercaptopurine. Gut 48, 591-592 (2001).
27. Meggitt, S.J., Gray, J.C. & Reynolds, N.J. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 367, 839-846 (2006).
28. Schmiegelow, K. et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24, 345-354 (2010).
29. Evans, W.E., Horner, M., Chu, Y.Q., Kalwinsky, D. & Roberts, W.M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119, 985-989 (1991).
30. Relling, M.V., Pui, C.H., Cheng, C. & Evans, W.E. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107, 843-844 (2006).
31. Lennard, L. Clinical implications of thiopurine methyltransferase- optimization of drug dosage and potential drug interactions. Ther. Drug Monit. 20, 527-531 (1998).
32. Krynetski, E.Y. & Evans, W.E. Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet. 63, 11-16 (1998).
33. Kaskas, B.A. et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 52, 140-142 (2003).